Alnylam and Medison Expand Global Partnership to Accelerate Access to Innovative Therapies

01 May 2024 | Wednesday | News


Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Image Source : Public Domain

Image Source : Public Domain

 
  • The expanded partnership will allow Alnylam and Medison to help accelerate access for patients in multiple regions under one global alliance
  • Medison, the creator and leader of the multi-regional partnership category, will utilize its unique, unified platform for efficient global commercialization of Alnylam's innovative RNAi technologies

Medison Pharma  a global pharma company focused on providing access to highly innovative therapies for patients in international markets, and Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced today a further expansion of their existing partnership in Central & Eastern Europe and Israel, to also include selected markets in LATAM and APAC and additional international markets.

Medison, the creator and leader of the multi-regional partnership category, has established a unique, unified commercialization platform in international markets, particularly for the treatment of rare and severe diseases. Medison is the only partner that focuses solely on the most innovative therapies.

Alnylam and Medison initially partnered in 2018. Ever since, the partnership has expanded to additional regions and markets, to ensure that Alnylam's commercial therapies, such as ONPATTRO® (patisiran), AMVUTTRA® (vutrisiran), GIVLAARI® (givosiran), and OXLUMO® (lumasiran) are made available across multiple international markets.

"We are delighted to extend yet again our existing partnership with Medison, which will enable us to enhance our presence and bring the benefits of Alnylam's innovative RNAi therapeutics to patients in additional APAC and LATAM markets," said Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam. "Medison is at the forefront of the global trend of consolidating international markets under one alliance. Together, we'll provide faster access to more patients around the world."

"The new category of the multi-regional partnerships that we have been creating in the past few years continues to get traction with the most innovative biotech companies," said Meir Jakobsohn, Founder and Executive Chairman of Medison. "We are proud of our longstanding partnership with Alnylam and will continue to work together to bridge geographical gaps, ensuring that Alnylam's life-saving therapies reach patients in need."

"Our unified commercial platform enables biotech companies to transform numerous complex and fragmented markets and regions into a unified territory, and we are proudly leading the trend and the category," said Gil Gurfinkel, CEO of Medison. "Our expanding partnership with Alnylam shows just how our one-of-a-kind unified commercial platform, with single alliance management across multiple markets and regions, is of great value to leading biotech companies. This partnership will make Alnylam's therapies available in additional international markets, offering newfound hope for patients suffering from rare diseases."

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close